Should Men with Prior CVD be Treated Preferentially with a GnRH Antagonist?

225Ac-LNC1011 targeted α therapy elicited an ORR of 50.0% in patients with PSMA-positive prostate cancer in a phase 1 trial.

Experts weigh in on the practical applications of PSMA PET imaging

The FDA did not expand the indication to include patients with non–homologous recombination repair gene mutated castration-resistant prostate cancer.

Steven E. Finkelstein, MD, DABR, FACRO discuses how Prolaris distinguishes itself from other genomic biomarker platforms by providing uniquely actionable clinical information that quantifies the absolute benefit of androgen deprivation therapy when added to radiation therapy, offering clinicians a more precise tool for personalizing prostate cancer treatment strategies.

Results from the phase 3 ARANOTE trial demonstrated a statistically meaningful improvement to rPFS with darolutamide vs placebo.

The addition of CAN-2409 to a prodrug and radiation therapy in intermediate-to-high-risk prostate cancer significantly improved cancer-specific outcomes.